Overcoming manufacturing bottlenecks to accelerate clinical trial supply chains.
Scalable Synthesis Pipelines for Next-Generation Antibody-Drug Conjugates
Dr. Elena Rostova · Switzerland
This presentation highlights a newly optimized, automated bioreactor system that doubles the yield of target monoclonal antibodies while minimizing batch-to-batch impurities. By refining the link technology, this scalable framework ensures highly stable conjugate delivery, drastically reducing production overhead for precision oncology therapeutics.